HK1198516A1 - 用於治療病毒感染的化合物和方法 - Google Patents
用於治療病毒感染的化合物和方法Info
- Publication number
- HK1198516A1 HK1198516A1 HK14112051.5A HK14112051A HK1198516A1 HK 1198516 A1 HK1198516 A1 HK 1198516A1 HK 14112051 A HK14112051 A HK 14112051A HK 1198516 A1 HK1198516 A1 HK 1198516A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- viral infections
- treating viral
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7279908P | 2008-04-03 | 2008-04-03 | |
US7279408P | 2008-04-03 | 2008-04-03 | |
US7442108P | 2008-06-20 | 2008-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1198516A1 true HK1198516A1 (zh) | 2015-05-15 |
Family
ID=41377864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14112051.5A HK1198516A1 (zh) | 2008-04-03 | 2014-11-28 | 用於治療病毒感染的化合物和方法 |
HK18110419.2A HK1250936A1 (zh) | 2008-04-03 | 2018-08-14 | 用於治療病毒感染的化合物和方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18110419.2A HK1250936A1 (zh) | 2008-04-03 | 2018-08-14 | 用於治療病毒感染的化合物和方法 |
Country Status (7)
Country | Link |
---|---|
US (4) | US8404651B2 (zh) |
EP (1) | EP2271351A4 (zh) |
KR (3) | KR101927905B1 (zh) |
CN (3) | CN102123716B (zh) |
GB (1) | GB2471806B (zh) |
HK (2) | HK1198516A1 (zh) |
WO (1) | WO2009146123A2 (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CA2744987C (en) | 2008-12-02 | 2018-01-16 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
CN107973833A (zh) * | 2010-08-30 | 2018-05-01 | 斯普林银行医药公司 | 作为治疗剂的寡核苷酸类似物的设计 |
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
RU2014105311A (ru) | 2011-07-19 | 2015-08-27 | Уэйв Лайф Сайенсес Пте. Лтд. | Способы синтеза функционализованных нуклеиновых кислот |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
AU2013266393B2 (en) | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
EA027929B1 (ru) | 2012-05-25 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Нуклеозиды на основе урацила и спирооксетана |
JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
MX356830B (es) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Adyuvante de acido nucleico quiral. |
SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
ES2674980T3 (es) | 2012-10-08 | 2018-07-05 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloro nucleósidos para infección por VHC |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
WO2014127378A2 (en) * | 2013-02-18 | 2014-08-21 | Spring Bank Pharmaceuticals, Inc. | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
KR102423317B1 (ko) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
US11701369B2 (en) | 2014-09-28 | 2023-07-18 | Huahui Health Ltd. | Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport |
US20190046552A1 (en) * | 2015-04-07 | 2019-02-14 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hcv infection |
CA2982125A1 (en) * | 2015-04-07 | 2016-10-13 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hbv infection |
WO2017004499A1 (en) * | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of viral infection |
WO2017011622A1 (en) * | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
EP3362460A1 (en) * | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
WO2017156391A1 (en) * | 2016-03-11 | 2017-09-14 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions for the treatment of infections |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
TW201821085A (zh) * | 2016-10-24 | 2018-06-16 | 美商春季銀行製藥公司 | 用於治療hbv感染的組合物及方法 |
CN110467646A (zh) * | 2018-05-09 | 2019-11-19 | 博瑞生物医药(苏州)股份有限公司 | 双核苷酸前体药物 |
CN113164506B (zh) * | 2018-12-06 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 二核苷酸化合物及其前体药物 |
CN111484540B (zh) * | 2019-01-25 | 2023-09-08 | 博瑞生物医药(苏州)股份有限公司 | 含双核苷酸结构的化合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2705099B1 (fr) * | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
AU4156197A (en) * | 1996-08-21 | 1998-03-06 | Hybridon, Inc. | Oligonucleotide prodrugs |
US20020127598A1 (en) * | 2000-03-27 | 2002-09-12 | Wenqiang Zhou | Solution-phase combinatorial library synthesis and pharmaceutically active compounds produced thereby |
BR0114837A (pt) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal |
US6961942B1 (en) | 2000-11-06 | 2005-11-01 | Microsoft Corporation | Bluetooth TDI and winsock interface |
WO2002092006A2 (en) * | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
US20060074035A1 (en) * | 2002-04-17 | 2006-04-06 | Zhi Hong | Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections |
US6641916B1 (en) | 2002-11-05 | 2003-11-04 | E. I. Du Pont De Nemours And Company | Poly(trimethylene terephthalate) bicomponent fibers |
US20040158054A1 (en) | 2003-02-07 | 2004-08-12 | Wu Jim Zhen | Di-ribonucleotides as specific viral RNA-polymerase inhibitors for the treatment or prevention of viral infections |
RU2005133093A (ru) * | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
WO2006002231A1 (en) * | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
BRPI0515896A (pt) * | 2004-09-24 | 2008-08-12 | Idenix Cayman Ltd E Ct Nat De | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus |
WO2006050161A2 (en) * | 2004-10-29 | 2006-05-11 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
BRPI0607769A2 (pt) * | 2005-02-28 | 2009-10-06 | Genelabs Tech Inc | pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais |
JP2008535932A (ja) * | 2005-03-09 | 2008-09-04 | イデニクス(ケイマン)リミテツド | 抗ウィルス剤としての非天然塩基を有するヌクレオシド |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
US20070293904A1 (en) | 2006-06-20 | 2007-12-20 | Daniel Gelbart | Self-powered resonant leadless pacemaker |
CA2747999A1 (en) * | 2008-12-23 | 2010-07-01 | Girindus America, Inc. | Sulfurizing reagents and their use for oligonucleotides synthesis |
BR112012000828A8 (pt) * | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
-
2009
- 2009-04-03 WO PCT/US2009/039424 patent/WO2009146123A2/en active Application Filing
- 2009-04-03 GB GB1018497.6A patent/GB2471806B/en not_active Expired - Fee Related
- 2009-04-03 CN CN2009801207783A patent/CN102123716B/zh not_active Expired - Fee Related
- 2009-04-03 EP EP09755485.1A patent/EP2271351A4/en not_active Withdrawn
- 2009-04-03 KR KR1020177034740A patent/KR101927905B1/ko active IP Right Grant
- 2009-04-03 KR KR1020167004420A patent/KR101806314B1/ko active IP Right Grant
- 2009-04-03 CN CN201711051066.3A patent/CN107753499A/zh active Pending
- 2009-04-03 KR KR1020107024633A patent/KR101620394B1/ko active IP Right Grant
- 2009-04-03 CN CN201310362314.1A patent/CN103816174B/zh not_active Expired - Fee Related
-
2010
- 2010-10-04 US US12/897,389 patent/US8404651B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/800,931 patent/US9138442B2/en not_active Expired - Fee Related
-
2014
- 2014-11-28 HK HK14112051.5A patent/HK1198516A1/zh not_active IP Right Cessation
-
2015
- 2015-08-11 US US14/823,359 patent/US9539276B2/en not_active Expired - Fee Related
-
2016
- 2016-12-02 US US15/367,552 patent/US10376533B2/en not_active Expired - Fee Related
-
2018
- 2018-08-14 HK HK18110419.2A patent/HK1250936A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR101620394B1 (ko) | 2016-05-12 |
KR101806314B1 (ko) | 2017-12-07 |
US20170304344A1 (en) | 2017-10-26 |
GB2471806A (en) | 2011-01-12 |
US20130197066A1 (en) | 2013-08-01 |
WO2009146123A2 (en) | 2009-12-03 |
CN103816174B (zh) | 2017-12-05 |
US9138442B2 (en) | 2015-09-22 |
US10376533B2 (en) | 2019-08-13 |
GB201018497D0 (en) | 2010-12-15 |
US9539276B2 (en) | 2017-01-10 |
GB2471806B (en) | 2012-12-19 |
EP2271351A4 (en) | 2016-08-31 |
CN107753499A (zh) | 2018-03-06 |
KR20170137947A (ko) | 2017-12-13 |
CN102123716A (zh) | 2011-07-13 |
US20160038527A1 (en) | 2016-02-11 |
CN103816174A (zh) | 2014-05-28 |
KR20100132058A (ko) | 2010-12-16 |
US20110207690A1 (en) | 2011-08-25 |
KR20160031021A (ko) | 2016-03-21 |
CN102123716B (zh) | 2013-09-18 |
EP2271351A2 (en) | 2011-01-12 |
HK1250936A1 (zh) | 2019-01-18 |
KR101927905B1 (ko) | 2018-12-11 |
US8404651B2 (en) | 2013-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250936A1 (zh) | 用於治療病毒感染的化合物和方法 | |
HRP20190214T1 (hr) | Pripravci i metode za liječenje purpure | |
WO2011056650A9 (en) | Methods and compositions for treating and preventing viral infections | |
HK1225316A1 (zh) | 治療病毒感染的方法 | |
EP2361089A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE | |
GB0816679D0 (en) | Compounds for treating viral infections | |
EP2120561A4 (en) | COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE | |
EP2124985A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS | |
IL210097A0 (en) | Compositions and methods for treating unfluenza | |
ZA201101055B (en) | Compositions and methods for treating osteoarthritis | |
EP2451795A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE EFFICACY OF A VIRUS | |
EP2282719A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | |
IL195272A0 (en) | Methods and compositions for the treatment of viral infections | |
EP2504428A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING | |
EP2355660A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
EP2249789A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY | |
EP2217573A4 (en) | TREATMENT AND PREVENTION OF VIRUS INFECTIONS | |
EP2663327A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS | |
ZA201202924B (en) | Compositions and methods for treating bacterial infections using ceftaroline | |
HK1167350A1 (zh) | 保護和治療神經損傷的方法和組合物 | |
EP2393506A4 (en) | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | |
EP2429290A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF AIDS AND HIV INFECTIONS | |
ZA201205639B (en) | Compositions and methods for treating hepatitis b virus infection | |
IL217764A0 (en) | Methods and compositions for treating leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220331 |